Pari eFlow rapid User manual

Cap and seal
Control unit
Power button
Connection cord socket
Medication reservoir
*
Aerosol head
Aerosol chamber
*
Inspiratory valve
Mouthpiece
Preassembled
nebuliser parts*
A quick reference guide. For full details, please read and take note of the Instructions For Use.
Assembly and inhalation
1
Assemble Hold the nebuliser horizontally to inhale
2
PARI GmbH – Spezialisten für effektive Inhalation, Moosstraße 3, D-82319 Starnberg, Tel: [phone] / 279 - 220
With mouthpiece
With mask (for ages 2 and older)
A note about the medication reservoir:
A small amount of medication that must not be used
is left in the reservoir. It must be disposed of. Similar
quantities of medication also remain unused in the
PARI LC PLUS®nozzle nebuliser.
* The aerosol chamber and the medication reservoir are preassembled
and cannot be taken apart.
PARI SMARTMASK®Kids (Part no. 078G5000)
© 2006 PARI GmbH · Spezialisten für effektive Inhalation · 178D0035 · 09/06
eFlow rapid Arzneimittelkarte für Ärzte EN 20.09.2006 14:05 Uhr Seite 1

Practitioner´s information: Inhalation therapy with eFlow®rapid:
Inhalation Solutions & Treatment Time
Active Agent
Concentration1)
Substance
Class1)
eFlow® rapid
Details
TOR
g/min 4)
MMD
μm 4)
RF %
< 5μm 4)
Time
Min
Tobramycin
300mg/5 ml
Aminoglycoside
Antibiotic
Serum level is comparable to standard therapy using
the PARI LC PLUS® nebuliser. Serum value approx.
1 μg/ml data on file (n=9).2)
Tested with TOBI®(Chiron/Novartis) 0.50 3.9 73 6-8
Colistimethate sodium
79 mg (1 Mio units)/3 ml
Polymyxine
Polypeptide Antibiotic
Colistin powder has to be dissolved carefully in 3 ml
0.9 % sodium chloride solution.
Tested with Colistin CF (Grünenthal) 0.58 3.9 69 3-4
Salbutamol
2.5 mg/2.5 ml
Bronchodilator
Beta 2 mimetic
Comparable treatment safety: Heart rate pre and post
delivery of Salbutamol (10 min after inhalation) is
comparable to LC PLUS® nebuliser. Data on file (n=10).2)
Tested with Sultanol®forte (Glaxo Smith Kline)
0.68 4.3 64 2-3
Ipratropiumbromide
500 μg/2 ml
Bronchodilator
Anticholinergic
Tested with Atrovent®(Boehringer Ingelheim) 0.69 4.3 63 1-2
Dornase alfa
2.5 mg/2.5 ml
Mucolytic agent Enzymatic activity remains largely stable
after nebulization (90%) as for PARI LC PLUS®
nebuliser 2)3). Tested with Pulmozyme®(Roche) 0.61 3.9 72 2-3
Acetylcysteine
300 mg/3 ml
Mucolytic Tested with Fluimucil®(Zambon) 0.60 4.1 70 4-5
Medical product:
Isotonic sodium chloride
solution (0.9 %) 2.5 ml
PARI NaCl Inhalation Solution
Secretolytic Individual treatment schedule.
Tested with PARI NaCl Inhalation Solution
0.70 4.3 67 2-3
Dispensed hypertonic
saline solution
(Sodium chloride 5.8%) 2.5 ml
Secretolytic Individual treatment schedule.
Tested with dispensed saline solution 5.8 % 0.69 4.2 69 2-3
1) These agents are approved for inhalation therapy in Germany. 2) Seemann et al: Improving aerosol drug delivery in CF therapy. European Cystic Fibrosis Society, 28 th European Cystic Fibrosis
Conference, Crete, Greece, June 22-25, 2005. 3) Lichtinghagen (2004 and 2005), MHH. 4) PARI internal tests, measured with the
Malvern MasterSizer X at 23°C and 50% relative humidity. Inspiratory flow 20 l/min. TOR, MMD, RF, time (mean values).
eFlow rapid Arzneimittelkarte für Ärzte EN 20.09.2006 14:05 Uhr Seite 2